Drug Profile
BIO 023
Alternative Names: BIO023Latest Information Update: 31 Mar 2011
Price :
$50
*
At a glance
- Originator Gardant Pharmaceuticals
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 31 Mar 2011 Discontinued - Phase-I for Psoriasis in USA (Injection)
- 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
- 22 Oct 2005 Phase-I clinical trials in Psoriasis in USA (Injection)